Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: File photo shows a young carer holding the hands of an elderly woman in a residential home for the elderly in Planegg near Munich June 19, 2007. REUTERS/Michaela Rehle The study, reported on Sunday in the journal BioMed Central BMC Neurology, involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth. "We often see verbal effects within a few minutes of the first dose," said Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical group inc., in Los Angeles, who led the study. Tobinick invented and holds several patents on a special method of injecting the drug into the neck. He said he charges anywhere between $10,000 and $40,000 per patient for the treatments. In January, Tobinick's report on a single patient, and release of a striking video, drew the attention of the Alzheimer's Association, which released a statement expressing concern. "People with Alzheimer's and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect," the group said. "We need to see work in other laboratories by scientists without financial interest in the product," it added. Dr. Sam Gandy, chairman of the Alzheimer's Association's medical and science council, said the latest study, done at Tobinick's clinic, does not offer that independent confirmation. "It's still not a proper trial," Gandy said. Tobinick believes the drug may work in the brain by blocking an excess of tumor necrosis factor-alpha or TNF-alpha, which may affect communication in the brain. The study looked at language difficulties, such as in finding words, in 12 patients with mild-to-severe Alzheimer's disease who were administered etanercept weekly for six months. "There was a significant improvement in the majority of the verbal measures that were studied. The remainder showed a tendency toward improvement, which was not significant," Tobinick said in a telephone interview. He said the study provides evidence that "excess TNF, in the Alzheimer brain, may offer a new way to address this language dysfunction." Tobinick acknowledged the study is limited because people knew they were getting the drug. Alzheimer's patients in such open-label studies often show improvement. "Placebo effect is an enormous problem in open-label studies," said Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington. Turner said the true test must come from a more scientifically rigorous double-blind, placebo-controlled, randomized clinical trial. In such studies, patients receive either a dummy treatment or an active agent, and neither the doctor nor the patient knows which. Amgen has also expressed concern about the research, claiming there has been insufficient evidence so far. "This off-label, unapproved treatment, administered by Dr. Edward Tobinick, is not supported nor endorsed by Amgen," the company said in April on its Web site. A video showing one woman's response to the drug in a sister study can be found at : here

Output: Drug restores speech in Alzheimer's; experts worry.

Input: Consider Input: "They are heroic, I think there is no other way to describe what they are doing at this moment," said Howard Catton, a British nurse who is the ICN's chief executive officer. Infection rates of 9% and 12-14% have been reported among health workers in Italy and Spain, respectively, and deaths among nurses there and in Iran and Indonesia, he said. "We have no doubt that the rate of infections is related in part to the lack of PPE - personal protective equipment," he told Reuters at the ICN offices along Lake Geneva. "There is a global shortage and nurses obviously are at a higher risk given the people that they are caring for." The federation represents 130 national associations and more than 20 million registered nurses. The World Health Organization has called repeatedly for countries and manufacturers to step up production of masks, gloves, gowns and other equipment for vulnerable health workers amidst critical shortages. Nearly 700,000 people have been infected worldwide in the outbreak that began last December in China and has claimed more than 33,000 lives, according to the WHO. Catton said there had been problems with supply chains in hard-hit Italy and Spain, describing their health systems as "very close to being overwhelmed". Nurses worldwide take samples from COVID-19 patients, give them medicines and oxygen, and help incubate those in serious condition. "They are working under intense pressure, often long hours, some working back-to-back shifts for days on end, even sleeping over in the hospital, the facility, in which they work." Some nurses have been forced to re-use their gear or make their own masks and gowns, he added. "Wearing personal protective equipment when it is available is not easy either...Simple things like going to the loo and eating are of course much more difficult," he said. Nurses across Africa and South Asia could be at greater risk as the virus moves to poorer settings. "We are very concerned that those countries that have weaker, more fragile health care systems could very quickly become overwhelmed by this virus if it takes hold in their countries," Catton said. Nurses in Zimbabwe, fearing for their own safety, have been on strike due to a lack of information and protective gear, he said.

Output: Heroic nurses need full protection against coronavirus, association says.

Input: Consider Input: No mention of costs The story quantifies the benefits in terms of survival for both intravenous and intraperitoneal chemotherapy. The story gives us balanced information on harms, including the very serious side effects which led to less than half the study population adhering to the full course of chemo. The story accurately represents the nature of the clinical evidence, that this was a controlled trial with 415 women. It should have been more clear that it was a randomized trial. The story accurately represents the prevalence of ovarian cancer and the survival. Independent source is quoted. The author does mention intravenous chemotherapy as the alternative and explains the advantages and disadvantages of the new approach. Clearly this treatment is available in the U.S., but it's not clear how widely available it is and how many oncologists have experience using it. The story does not mention if the treatment is new or not.
Output: Treatment brings hope for ovarian cancer